Sabra Health Care price target raised to $18 from $17 at Truist

Truist raised the firm’s price target on Sabra Health Care (SBRA) to $18 from $17 and keeps a Hold rating on the shares. The risk of recession has increased and the 10-year Treasury rate has fallen since the firm’s downgrade of the stock in January, the analyst tells investors in a research note. Notwithstanding risks to Medicaid funding, select healthcare REITs might generally be relatively defensive within the sector if macroeconomic trends continue to worsen, Truist adds.